← Leaderboards
Michael Reiss
Incyte Pharmaceuticals, Inc.
$7,198,417
Attributed
$7,198,417
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2005–10$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
Funding mix
By agency
NIH$7,198,417 · 6
By mechanism
R01$5,582,180 · 3
U01$1,002,425 · 1
T32$409,812 · 1
N01$204,000 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Transforming Growth Factors”
- J. Mark Cline · Wake Forest University$19,830,326
- Martin M Matzuk · University Of Missouri-Columbia$19,151,455
- Joan Massague · Sloan-Kettering Institute For Cancer Res$17,872,570
- Xu Cao · Johns Hopkins University$16,160,002
- Jae U Jung · Cleveland Clinic Lerner Com-Cwru$15,688,012
- Kathryn M Anastos · Montefiore Medical Center (Bronx, Ny)$15,465,311
Research focus
Transforming Growth FactorsReceptorResponseMalignant NeoplasmsPhenotypeInhibitor/AntagonistTumorTissuesGenomicsSignal TransductionInjuryMediatingCellsHomeostasisGrowth Factor ReceptorsKeratinocytePhosphotransferasesTransforming Growth Factor BetaGrowthAngiogenesisCancer CellPlayOncogenicProperty
Grant awards (26)
Targeting Transforming Growth Factor-beta in Metastatic Breast Cancer$299,882
R01 · FY2010 · CA · contact PI
Targeting Transforming Growth Factor-beta in Metastatic Breast Cancer$299,882
R01 · FY2009 · CA · contact PI
TGFBeta Receptor Mutations in Cancer and Other Diseases$293,299
R01 · FY2009 · CA · contact PI
GROWTH CONTROL OF NORMAL AND MALIGNANT KERATINOCYTES$331,745
R01 · FY2008 · CA · contact PI
Targeting Transforming Growth Factor-beta in Metastatic Breast Cancer$299,882
R01 · FY2008 · CA · contact PI
TGFBeta Receptor Mutations in Cancer and Other Diseases$293,299
R01 · FY2008 · CA · contact PI
GROWTH CONTROL OF NORMAL AND MALIGNANT KERATINOCYTES$177,091
R01 · FY2008 · CA · contact PI
GROWTH CONTROL OF NORMAL AND MALIGNANT KERATINOCYTES$331,745
R01 · FY2007 · CA · contact PI
TGFBeta Receptor Mutations in Cancer and Other Diseases$306,574
R01 · FY2007 · CA · contact PI
Targeting Transforming Growth Factor-beta in Metastatic Breast Cancer$299,802
R01 · FY2007 · CA · contact PI
GROWTH CONTROL OF NORMAL AND MALIGNANT KERATINOCYTES$172,386
R01 · FY2007 · CA · contact PI
GROWTH CONTROL OF NORMAL AND MALIGNANT KERATINOCYTES$341,653
R01 · FY2006 · CA · contact PI
GROWTH CONTROL OF NORMAL AND MALIGNANT KERATINOCYTES$167,817
R01 · FY2006 · CA · contact PI
GROWTH CONTROL OF NORMAL AND MALIGNANT KERATINOCYTES$349,875
R01 · FY2005 · CA
GROWTH CONTROL OF NORMAL AND MALIGNANT KERATINOCYTES$349,875
R01 · FY2004 · CA
TGFBeta receptor antagonists as anticancer agents$258,417
U01 · FY2004 · CA
GROWTH CONTROL OF NORMAL AND MALIGNANT KERATINOCYTES$324,040
R01 · FY2003 · CA
TGFBeta receptor antagonists as anticancer agents$250,889
U01 · FY2003 · CA
GROWTH CONTROL OF NORMAL AND MALIGNANT KERATINOCYTES$317,660
R01 · FY2002 · CA
TGFBeta receptor antagonists as anticancer agents$243,581
U01 · FY2002 · CA
GROWTH CONTROL OF NORMAL AND MALIGNANT KERATINOCYTES$310,940
R01 · FY2001 · CA
TGFBeta receptor antagonists as anticancer agents$249,538
U01 · FY2001 · CA
MEDICAL ONCOLOGY, HEMATOLOGY, AND PHARMACOLOGY$166,235
T32 · FY2001 · CA
GROWTH CONTROL OF NORMAL AND MALIGNANT KERATINOCYTES$314,733
R01 · FY2000 · CA
MEDICAL ONCOLOGY, HEMATOLOGY, AND PHARMACOLOGY$243,577
T32 · FY2000 · CA
INCYTE MICROARRAY SERV IN SUPPORT OF THE PRB$204,000
N01 · FY2000 · HD